IBD in Clinical Practice: Long-term Disease Management and Surgery - 2017


IBD in Clinical Practice: Long-term Disease Management and Surgery - 2017

Topic: Gastroenterology
Relevant Terms: inflammatory bowel diseases; Crohn's disease; ulcerative colitis
Primary Audience: Physicians and gastroenterologists, nurse practitioners and physician assistants
Launch Date: 04-May-17
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Inflammatory Bowel Diseases in Clinical Practice: An Interactive Tutorial for Patient...

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Decide which medical treatment to use in acute IBD flares and for long-term disease management
  2. Identify IBD characteristics for which surgery is indicated


    Hans Herfarth, MD, PhD
    Professor of Medicine
    University of North Carolina
    Chapel Hill, NC
    Miguel Regueiro, MD
    Professor of Medicine
    Co-Director of the Inflammatory Bowel Disease Center

    University of Pittsburgh Medical Center
    Pittsburgh, PA
    A fact sheet from the Crohn’s and Colitis Foundation describes the infliximab and adalimumab biosimilars and other recently approved therapies for IBD:  http://www.ccfa.org/assets/pdfs/recently-approved-treatments.pdf
    Reading Resources:
    1. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553-1563.
    2. Jones J, Peña-Sánchez JN. Who should receive biologic therapy for IBD?: The rationale for the application of a personalized approach. Gastroenterol Clin North Am. 2014;43(3):425-440.
    3. Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment for inflammatory bowel disease, from clinical trials and practice. Gastroenterology. 2014;148(1):37-51.
    4. Mosli MH, Sandborn WJ, Kim RB, Khanna R, Al-Judaibi B, Feagan BG. Toward a personalized medicine approach to the management of inflammatory bowel disease. Am J Gastroenterol. 2014;109(7):994-1004.
    Hans Herfarth, MD, PhD, has affiliations with Celltrion, Merck, Pfizer, Samsung (Consultant).
    Miguel Regueiro, MD, has affiliations with AbbVie, Celgene, Janssen, Miraca, Pfizer, Takeda, UCB (Consultant).
    Authors disclosure of relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above.  No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose. 
    Accreditation Statement:
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Pittsburgh School of Medicine and Crohn's & Colitis Foundation. The University of Pittsburgh School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    The University of Pittsburgh School of Medicine designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Each physician should only claim credit commensurate with the extent of their participation in the activity.
    Other health care professionals are awarded .05 continuing education units (CEUs), which are equal to 0.5 contact hours. Faculty for this activity have been requested to identify significant financial or other relationships with manufacturer(s) of any commercial product(s) or with provider(s) of any commercial service(s) which might affect the balance of their presentation.
    Estimated time to complete: 30 minutes
    Medium: Internet

    There is no fee for this educational activity.

    This activity is jointly provided by The University of Pittsburgh School of Medicine and the Crohn's & Colitis Foundation. This activity is supported by independent educational grants from AbbVie Inc., Salix Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc.
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive AMA PRA Category 1 Credits™.
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive AMA credit. You must score a 75% or higher on the post-test to receive credit for this activity. You will have three attempts to take the post-test.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 5.0+ for Mac OSX 10.5 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above